

# cgtd-development

GLOBAL INNOVATION SUMMIT 2025

21-22 MAY 2025 BOSTON USA

CELL & GENE INNOVATION OVERCOMING CURRENT LIMITATIONS IN CGT BIOPROCESSING, MANUFACTURING, SUPPLY CHAIN & COMMERCIALIZATION

draft edition



## MANUFACTURING AND BIOPROCESS

**REVOLUTIONISING SUPPLY & VALUE CHAIN AUTOMATION & ORCHESTRATION:** Standardize Best Practice in Planning, Communication & Scale Up to Consistently Deliver Safely, on Time & in a Cost-Effective Process

## SUPPLY CHAIN AND LOGISTIC

**DOWNSTREAM MANUFACTURING OF GENE THERAPY VECTORS:** Viral Vector Development, Manufacturing, and Process Intensification. Accelerated Development, Manufacturing and Monitoring of Viral Vectors.

## QUALITY COMPLIANCE COMMERCIALIZATION

**REVOLUTIONISING SUPPLY & VALUE CHAIN AUTOMATION & ORCHESTRATION:** Managing product quality across an increasingly diverse and global manufacturing network

## PRICING AND MARKET ACCESS

**OVERVIEW OF AVAILABLE REGULATORY PATHWAYS TO ACCELERATE DEVELOPMENT FOR ADVANCED THERAPIES** Strategies For Commercial Success, getting ahead the upcoming challenges.



**Roberto Nitsch**

Director  
Gene Therapies

**AstraZeneca**



**Shawn Liu, Ph.D**

President & CEO

**Avirmax Inc**



**James Warren**

VP, Pharmaceutical  
Development

**Ultragenyx**



**Vladimir Slepushkin**

Executive Director,  
Vector Technology

**Autolus**

### INNOVATION PARTNERS



BIA Separations is now part of Sartorius



21st & 22nd MAY 2025 US  
[cgtd-development.com](http://cgtd-development.com)

### MEDIA





## **CONTINUALLY PUSHING THE BOUNDARIES OF INNOVATION CELL AND GENE THERAPY CAPABILITIES**

**The cgt-development, Global Innovation Summit 2025 is the Leading Cell & Gene Therapy leaders forum; dedicated to innovation, advancing production & commercialisation**

**Innovation is the process of turning new ideas into value. Recent years have seen Cell & Gene Therapies potential, realised into new products, services and methods like never before; along with creativity and invention to make the practical steps necessary for the adoption of next generation technologies and strategies and, in turn, laying the foundation for continued industry growth. Many leaders in Cell & Gene Therapies communities have priorities innovation as a key goal for long-term productivity and economic growth knowing that innovative firms significantly outperform non-innovators, in terms of both revenue and employment growth**

Proudly presenting the highly anticipated and exciting 2025 program, comprised of renowned world class speaker and industry thought leaders. Following comprehensive research using data from attendee surveys results, investment analytics platforms and media partners, undertaken with an expert panel advisory board. The program is rich with cutting-edge content on innovation and pivotal breakthroughs; giving you insight on the latest industry trends and technologies impacting Cell & Gene Therapies.

The leaders networking forum set to help pioneering professionals boost success and growth by providing a robust modern era leaders event platform that is highly informative and delivers a dynamic environment to benchmark, learn, engage, debate, procure and interact at the highest level. Make the right deals, with the right partners at the right time utilising a networking platform; designed particularly for decision makers to enhance overall experience and provide specialist business information.

# INNOVATE - COLLABORATE - ADVANCE

## Revolutionize Your Cell, Gene and CAR-T Programs

Network with the world's smartest leaders to share experience, ideas, innovations and expertise.

The **CGT-development Innovation Summit 2025** is a leading executive gathering committed to creating an advanced networking platform to increase innovation and collaboration within the Cell & Gene Therapy area. Our unique model is designed particularly to complement networking and communication exclusively for decision makers to enhance overall experience and provide specialist business information.

**Overcome key challenges:** Ensuring technological and operational supremacy and retain success with proven next generation strategies and approaches streamlined to obtain seamless integrated success in Cell & Gene Therapy development life-cycle from discovery in the lab to clinical and commercial scale production.

**60+**  
DISTINGUISHED  
SPEAKERS

**18**  
HOURS  
OVER 2 DAYS

**150**  
COMPANIES

**200+**  
INDUSTRY  
LEADERS



**Alain Bernard Ph.D**  
SVP Technical  
Operations  
**UCB**



**Manal Morsy, MD, PhD, MBA**  
EVP, Head of Global  
Regulatory Affairs  
**Athersys**



**Dave Kolwyck**  
VP Manufacturing  
Science, Raw Materials  
**Biogen Idec**

## cg<sub>t</sub> development GLOBAL INNOVATION CONGRESS

From interactive workshops, insightful panel discussions and ground-breaking keynotes, The program is specifically curated for you to make the most of your time at the summit.



World Class  
Leading Speakers



Leaders Panel  
Discussions



Industry Leading  
Distinguished Keynotes



One-to-One  
Meetings



10 Streams of  
Content



Exhibition  
Showcases



Interactive Round Tables



Breakthrough  
Innovation Spotlights



Peer-to-Peer  
In-Person & Digital Networking



Champagne  
Reception



Gala Dinner &  
Networking Lunches



Breakthrough Case Studies



# cgtd-development

## GLOBAL INNOVATION SUMMIT

Delegates typically include CEO, CMO, CSO, VP's, Directors, General Managers, and Heads of the following titles:

“Content is rich with cutting edge strategic intelligence and technological innovation”



**Keynote Speaker**

**Uwe Gottschalk**  
Chief Technology Officer

*Lonza*



Cell and Gene Manufacturing

Patient Access

Cell & Gene Bioprocess

Investigational Material Supply Chain

Personalized Medicines

AAV Viral Vector

Next Gen Facility Design

Immunotherapy Oncology

Gene Editing

Gene Therapy for Rare Diseases

Stem Cells & Regenerative Medicine

Regulatory Affairs

Biomedical Engineering

Digitalization \ Automation

Scale-Up Strategies

Clinical CART

Tissue Engineering

Pricing & Reimbursement

Emerging Therapies

Collaboration/ Outsourcing

## THEMES IN DISCUSSION

**The CGT-development Innovation Summit brings you the latest Cell, Gene & CAR-T Production Technologies and Commercialization Strategies. Themes for 2025 include:**

- **Innovations in Process Development and Manufacturing Driving the Future of Cell & Gene Therapy development:** Avoid pitfalls and reduce bottlenecks, implementing new breakthrough processing methodologies, technologies and approaches to improve quality, yield and capacity.
- **Understanding all strategic options in an unprecedented era of expedited regulatory pathways:** Examining and defining the potential value for industry in accelerated development and conditional approval pathways from around the globe.
- **Novel Gene Editing Applications in CART:** Understand next generations technologies in adoptive T cell Immunotherapy.
- **High Yielding AAV Platforms for Gene Therapy:** Examining continued innovation in Gene therapies.
- **Novel AAV Capsids for Gene Therapy:** Discovery, Characterization and Manufacturing.
- **Enabling more Precise, Efficient and Safer Genome Editing & Quantifying its Outcomes:** Innovation in repurposing of CRISPR-Cas 9 and all its variants. NextGen tools for on and off target effects when using different enzymes & variants.
- **Fundamental evolution to meet ATMP Quality and Process Challenges:** Implementation of next generation digital bioprocessing 4.0 and integrating automation technology for Increased GMP compliance and consistency. Enabling acceleration of processing research and scale-up considerations.
- **Will Allogeneic Replace Autologous Therapies?** Current industry trends and latest technological breakthroughs.
- **Novel Gene Editing Applications in CART:** Understand next generations technologies in adoptive T cell Immunotherapy
- **CAR and T CELL Therapies:** Pioneering point of care with innovative manufacturing and commercialization strategies: Revolutionizing cell and gene engineering - ground breaking autologous and allogeneic treatments for blood borne and solid tumours.
- **Achieving commercial scalability with 'facilities of the future' in patient-specific therapies:** Develop a "fit-for-purpose" development pathway that is associated with "faster to market" options for clinical development.
- **Technologizing ATMP/Cell and Gene Therapy:** Lentiviral vector manufacturing and analytics – opportunities, challenges and ways forward. The use of high-throughput technologies to facilitate cell line characterization and development, Evaluation of novel harvest methods for the clarification of cell culture material, Delivering a globally compliant allogeneic cell therapy - setting the benchmark.

## PROGRAM CHAIRMAN



Dr. Aleš Štrancar  
Managing Director  
BIA Separations,  
part of Sartorius Group

# INNOVATION SPOTLIGHTS

ACCESS THE RIGHT INTELLIGENCE TO DESIGN YOUR FUTURE WITH CONFIDENCE

**FUNDAMENTAL EVOLUTION  
TO MEET ATMP QUALITY AND  
PROCESS CHALLENGES**

**NEXT GEN TECHNOLOGY  
CELL & GENE THERAPY  
FACILITY DESIGN**

**REGULATORY PATHWAY TO  
COMMERCIAL SUCCESS**

**SUPPLY CHAIN  
AND LOGISTIC**

**Millipore  
Sigma**



TBA

Automation technology for Increased GMP compliance and consistency. Enabling acceleration of processing research and scale-up considerations.

increased GMP compliance and consistency. Enabling acceleration of processing research and scale-up considerations. Overcoming regulatory barriers in manufacturing Cell & Gene Therapies updates and pain points: Developing a robust, defendable and practical control strategy to reduce cost and decrease regulatory overhead.



**Guillaume Plane**  
Global Development  
End-to-End Solutions  
Millipore Sigma

Overcoming challenges with multi-product capability, moving towards flexible manufacturing, automated processing and systems implementation.

Achieving commercial scalability with 'facilities of the future' in patient-specific therapies:

Develop a "fit-for-purpose" development pathway that is associated with "faster to market" options for clinical development.



TBA

Understanding all strategic options in an unprecedented era of expedited regulatory pathways: Examining and defining the potential value for industry in accelerated development and conditional approval pathways from around the globe.

Development Cell Therapy Scale-Up Strategies For Commercial Success: Getting ahead the upcoming challenges. Recalibration in development of reimbursement model for therapies that go beyond the traditional approach To disease treatment.






TBA

Overcoming challenges with ageing plants moving towards flexible manufacturing, automated processing and systems implementation

Achieving commercial scalability with 'facilities of the future' in patient-specific therapies:

Develop a "fit-for-purpose" development pathway that is associated with "faster to market" options for clinical development.

# PROGRAM: DAY 1 MORNING - HARBOUR VIEW BALLROOM

08:00	Registration And Networking Breakfast	
08:50	<b>Chairman's Welcoming And Opening Address</b> Chairperson's Congress Address Evolution v Revolution: which changes are driving our industry and where are they leading us to?	
09:00	<b>Opening Keynote</b> <b>Streamlining Cell and Gene Therapy Production:</b> Next-Generation Process Development and Manufacturing Strategies for Enhanced Efficiency and Cost Savings	TBA
09:45	Evolution of Biologics Development	<b>Henrick Anderson</b> VP Biologics Development 
10:15	<b>Exhibitors Innovation Spotlights</b> An Introduction and profile summary from BioManufacturing Global Innovation Exhibitors	
10:30	<b>Morning Refreshments - Served at the Exhibition Area</b>	
10:45	Developing a robust, defensible and practical control strategy to reduce cost and decrease regulatory overhead	<b>Dr Alain Bernard</b> VP Tech Operation 
11:15	<b>Fast AAV manufacturing process development by using dedicated HPLC system</b> - Fast and reliable in HPLC methods to allow for process optimization and assessing the purity of the final product using PATfix system will be presented.	<b>Ales Strancar</b> Managing Director  <small>BIA Separations is now part of Sartorius</small>
11:45	<b>Smart manufacturing approaches in facilities design/upgrades:</b> Overcoming challenges with ageing plants moving towards flexible manufacturing, automated processing and systems implementation	TBA

PROCESS DEVELOPMENT & COMMERCIAL STRATEGIES

ROBOTICS AND ASEPTIC FILLING



TBA

Title:  
From cells to purified capsids: How to develop a scalable rAAV process



**Keith Dodson**  
Vice President of  
Global Business Development

**Reinventing Your Aseptic Processing with Flexible Robotic Manufacturing.**  
Learn about putting quality first in aseptic fill-finish using the newest technologies in flexible robotic manufacturing.



12:45  
-  
14:15

**Networking Lunch - Served at the Exhibition Area - Live Innovation Showcase Demos**

**Pre-Arranged One to One Boardroom Meeting**

Allocated Board Rooms. All delegates without meetings can go to the exhibition area to be served lunch and network.

Pre-Scheduled Meeting 1 - 13:00

Pre-Scheduled Meeting 2 - 13:15

Pre-Scheduled Meeting 3 - 13:30



# PROGRAM: DAY 1 AFTERNOON - SESSIONS AND WORKSHOPS

14:15

## STREAM KEYNOTE

## STREAM KEYNOTE

## STREAM KEYNOTE

### QUALITY AND COMPLIANCE COMMERCIALIZATION

### CELL THERAPY

### BIOPROCESSING & MANUFACTURING



**Manal Morsy, MD, PhD, MBA**  
EVP, Head of Global  
Regulatory Affairs

TBA

TBA

Expedited regulatory pathways from bench to market

- Expedited Development Pathways
- Expedited Regulatory Review Pathways
- Expedited Regulatory Approval Pathways

Revolutionizing Autologous Cell Therapy Production:  
An Autonomous Biomanufacturing Platform for Scalable and  
Efficient Generation of iPSC-Derived Therapies

Streamlining Recombinant Adeno-Viral Vector Production:  
Leveraging Continuous Processing to Intensify Downstream  
Manufacturing and Enhance Efficiency

14:45

TBA



**Jessica Rage**  
Vice President  
Global Clinical Oncology



**Chao Huang, Ph.D.**  
Director  
Downstream Process Development

Adoptive T cell immunotherapy business models:  
Who has the lead in removing barriers to commercial success?  
Addressing the most pressing challenges facing the adoptive  
T cell therapy space today.

Balancing regulatory requirements with process optimization for  
commercial feasibility in advanced stage T-Cell therapy products.

Immunotherapy and targeted therapy spheres: Which  
combination therapy strategies will help realize the full  
potential? Honing combination therapy clinical strategies  
involving CAR T cell and TCR immunotherapy products  
candidate.

Global Strategy to Enrich Full Capsids in Adeno-associated Viral  
Vector Based Gene Therapy Downstream Process Development.

15:15

## Afternoon Refreshments - Served at the Exhibition Area

14:45



**Dr. Tom Spitznagel,**  
SVP, BiopPharmaceutical  
Development and Manufacturing



**John Tomfishen**  
Vice President  
Operations



**David Gruber**  
Director  
BioProcess Development

Evolution of a Robust Bispecific DART® Molecule Manufacturing  
Platform at MacroGenics

Innovating the Cell Therapy Manufacturing Paradigm

- Are we meeting the needs of our patients?
- What does the industry need?
- How can we change the manufacturing paradigm to meet the needs of our patients?

New developments in chromatography: Overcoming current  
Challenges in developing Purification Platforms to alleviate  
Bottlenecks. How will this shape the future of protein purification?

# PROGRAM: DAY 1 AFTERNOON STREAMS

Ballroom: Consitution

Ballroom: Faneuil

Ballroom: Quincy

## QUALITY AND COMPLIANCE

## CELL THERAPY

## PURIFICATION

16:00



**Chun Zhang**

Snr. Director, Manufacturing  
Sciences & Operations Support

Creating patient-specific manufacturing system for commercial production: Enabling commercialisation by Innovation and out of the box thinking.



**Vladimir Slepushkin**

Executive Director  
Vector Technology

Gene edited ex vivo cell therapy accelerating viral vector.  
Development of retroviral and lentiviral vectors for CAR-T therapy.



**David Roush**

Principal Scientist  
Purification

Leveraging technology innovation to overcome the direct impact of high titer processes In downstream processing.

## KEY TOPICS OF DISCUSSIONS

- Examining the shortages in manufacturing capacity - A global problem with local consequences
- Achieving commercial scalability with 'facilities of the future' in patient-specific therapies:
- Pragmatic Implementation of Single-use Technologies to Reduce the Time and Resource Required to Deliver Clinical Supply.
- Preventing product variation and maintaining quality (Risk management strategies, raw material qualification, QbD)
- Successful tech transfer of gene and cell therapy products: exploring the differences/risks particular to these products.

Have a question of discussion or debate for the leaders panel discussion? Use the interactive features interface and join in.



**Dr. Tom Spitznagel**

Senior Vice President  
BioPharmaceutical  
Development



**Dr. Aleš Štrancar**

Managing Director



**Roman Necina**

Chief Technology  
Officer



**Henrick Anderson**

Vice President  
Biologics Development



TBA



**Dave Kolwyck**

Vice President  
Manufacturing Science  
Raw Materials



# PROGRAM DAY 1: EVENING - CHAIRMAN'S CLOSING REMARKS & NETWORKING GALA

17:15 Day One Chairmans Closing remarks

Ales Strancar  
Managing Director



17:25 Champagne Reception - Exhibition Area



## NETWORKING GALA DINNER

18:00 Harbour View Ballroom

Finishing off the program on day one the champagne reception and gala dinner provides the perfect setting to following on from networking encounter's throughout the day, discuss development opportunities with familiar peers or to just simply enjoy the food and evaluate what you've learnt throughout the day in the finest environment corporate hospitality has to offer. The winner of the business card lucky dip will also be announced giving you the opportunity to win a great prize.



### Gala Dinner Hosted BY BIA Separations



End of Day 1

# PROGRAM: DAY 2 MORNING - KEYNOTES

## HARBOUR VIEW BALLROOM

09:00	<b>Day 2 Opening Address</b>	TBA
09:15	<b>Evaluating NextGen Technology:</b> Accelerating progress in a slow moving industry trapped between regulatory constraints and innovation.	<b>Lada Laenen, Sc.D.</b> SVP, Global Head Manufacturing Sciences and Technology 
09:45	<b>Quality as a Culture</b>  Establishing a quality mindset across manufacturing and operations. Examining the cost of compliance and striking a careful balance between quality and cost management	TBA
10:30	<b>Morning Refreshments - Served at the Exhibition Area</b>	
10:45	<b>End-to-End Solutions Considering New Trends in Biomanufacturing:</b> The current state of biomanufacturing, from DNA to market approval, considering the way a key supplier can support drug makers to the fullest, thanks to a deep understanding of the trends that could affect our industry in the midterm, including growth of the pipelines, strengthening of regulations, and acceleration of time lines, for development as well as for the set-up of capabilities	<b>Guillaume Plane</b> Global Development and Marketing Manager BioReliance® End-to-End Solutions. 
11:15	<b>Successful tech transfer strategies; particularly in current climate of M&amp;As:</b> effectively bridging the functions of manufacture, process development and quality Strategies in knowledge management and technology transfer.	TBA
11:45	<b>Use of High Throughput Technologies for Process Characterization and Process Validation</b>	TBA

# NETWORKING LUNCH & THEMED DISCUSSION GROUPS

12:00 -13:30

Discussion groups and Networking Lunch Served in Ballroom B

## Pre-Arranged One to One Boardroom Meeting

Allocated Board Rooms. All delegates without meetings can go to the Ballroom to be served lunch and participate in themed discussion groups.

Pre-Scheduled Meeting 4 - 12:30

Pre-Scheduled Meeting 5 - 12:45

Pre-Scheduled Meeting 6 - 13:00

Pre-Scheduled Meeting 7 - 13:45

### AUTOLOGUS CELL THERAPY PRODUCTION

### AAV VECTOR PURIFICATION

### AAV VECTOR CHARACTERIZATION

Innovating the Cell Therapy Manufacturing Paradigm

- Are we meeting the needs of our patients?
- What does the industry need?
- How can we change the manufacturing paradigm to meet the needs of our patients?

Global Strategy to Enrich Full Capsids in Adeno-associated Viral Vector Based Gene Therapy Downstream Process Development.

•



TBA



TBA

TBA

### REGENERATIVE MEDICINES

### PRICING & REIMBURSEMENT

### DECENTRALIZED CLINICAL MAUFACTURING

Innovating the Cell Therapy Manufacturing Paradigm

- Are we meeting the needs of our patients?
- What does the industry need?
- How can we change the manufacturing paradigm to meet the needs of our patients?

TBA

TBA



**Guillaume Plane**  
Global Development Manager  
End-to-End Solutions.

Ballroom: Consitution

Ballroom: Faneuil

BIOMANUFACTURING 4.0

CELL LINE DEVELOPMENT



TBA

13:30

**Title:**  
**Highly automated and innovative Manufacturing analytical solutions:** Find out how to automatically reveal and quantify undesired process outcomes.



**Henry Chiou**  
Director of Product Management,  
Protein Expression & Transfection

**Title:**  
**Advancing AVV cell lines Expression System for cell therapies.**



# PROGRAM: DAY 2 AFTERNOON - SESSIONS AND WORKSHOPS

14:15

STREAM KEYNOTE

STREAM KEYNOTE

STREAM KEYNOTE

## 4.0 ANALYTICS, AUTOMATION, SUPPLY CHAIN

## GENE THERAPY

## BIOPROCESSING & MANUFACTURING

TBA

TBA

TBA

Dynamic Supply Chain Resilience: Leveraging Digital Innovation for Agile Response to Market Fluctuations and Unforeseen Challenges

Revolutionizing Process Development: Preparing for the Commercial Scale-Up and Manufacturing of the First Approved Gene Editing Therapy

Addressing viral vector capacity dilemma: Evaluating the unique challenges in the manufacturing of viral vectors. How to developing scalable and cost-efficient manufacturing processes. Examining GMP compliance and what requirements need to be met; ensuring products are well-characterized and manufactured to high purity, efficacy, and safety

14:45



**Dave Kolwyck**  
VP Manufacturing Science  
Raw Materials



**Shawn Liu Ph.D**  
President & CEO



**Larry Sun**  
Director  
Upstream Processing

Implementation of "End to End" process control from raw materials to protein product quality enabling Pharma 4.0 manufacturing. Advances in integrating raw material characterization and handling operations with our strategic suppliers.

High titer and Quality AAV production, AAV analytics and AAV viral safety

- 

Process Intensification And Manufacturing Strategies For CAR-T Therapies. Demonstrating the consistent and scalable expansion of CAR-T cells from multiple donors in stirred- tank bioreactors. Approaches to reduce the variability and scalability issues of advanced therapies. Establishment of a control strategy for CAR-T process intensification.

15:15

**Afternoon Refreshments - Served at the Exhibition Area**

14:45

TBA



**Dr. Fulvio Mavilio**  
Scientific Director



**Jianmei Kochling,**  
Director,  
Analytical MSAT  
Global Manufacturing

Digital Transformation Tactics & Strategies  
Driving Performance in Biopharmaceutical Manufacturing through Digital Analytical and Automation Innovation.

Comparing and contrasting lentiviral, retroviral and other emerging cell transfection approaches for ex vivo gene therapy .

Preventing product variation and maintaining quality: Forced-degradation study challenge and strategy for biologics comparability studies, monitoring aggregation, characterization, stability and qualification.



# PROGRAM: DAY 2 AFTERNOON

Ballroom: Consitution

Ballroom: Faneuil

Ballroom: Quincy

## SUPPLY CHAIN LOGISTICS

## GENE THERAPY

## BIOPROCESSING TECHNOLOGY & MANUFACTURING STRATEGY

16:00

TBA

TBA

TBA

Addressing supply chain strengths and weaknesses to create better production planning for lifecycle management : How ready is the industry for the tidal wave of biopharma demand? Examining specific product categories and their associated supply risks. From clinical to launch: Best techniques for demand and uncertainty

Successful tech transfer of gene and cell therapy products: exploring the differences/risks particular to these products

Revolutionizing Autologous Cell Therapy Production: An Autonomous Biomanufacturing Platform for Scalable and Efficient Generation of iPSC-Derived Therapies

16:30

### Closing Keynote

Innovation as an avenue to pursue, to drive bioprocess performance up and cost down.

TBA

17:00

### Reflections on the Congress

Program Chairman

Dr. Aleš Štrancar

Managing Director



BIA Separations is now part of Sartorius


17:10

Closing Comments - Weiser West Research

# VENUE

**A world class venue in Boston will Cell & Gene Therapy Development, Innovation Summit 2025.**

Modern Era leadership networking platform provides the perfect ambiance for leaders to congregate, bringing together the smartest people to share their experience, ideas, innovations and expertise. Access the right intelligence and technologies to design your future with robust strategies in confidence.



**“**  
*A major global hub, Boston has a unique Cell and Gene DNA and culture; one that is collaborative in nature*  
**”**

**EXCLUSIVELY INVITES INFLUENTIAL SENIOR LEVEL EXECUTIVES WITH THE HIGHEST CREDENTIALS**

**Selection of pioneering leaders**

COMPANY	TITLE
Abbvie	Director Engineering Operations
Abbvie	Head of Microbial Manufacturing
Actogenix	Director CMC Operations
Actogenix	Director Of Manufacturing
Ark Therapeutics	Director Supply Chain
Adello Biologics	CSO
Agensys	Director, Quality
Astrazeneca	Senior Director, Immuno-Oncology, Global Medicines Development
Austrian Centre of Biotechnology	Laboratory of Cell Gene Technology
Baxter	Manager Cell Gene Therapy
Baxter AG	Project Team Leader Upstream Development
Baxter BioScience	Senior Director Operational Excellence
Bayers Global Biological Development	Director of Isolation & Purification
Bayers Global Biological Development	Senior Manager, Cell Gene Therapy
Biogen Idec	VP Technical Development
Biogen Idec	VP Supply Chain
Boehringer Ingelheim	Director of Downstream Process Development
Boehringer Ingelheim	Associate Director Upstream Processing Technology
BMS	Head of Cell Gene Therapy Production
BMS	Director Operational Technical Support
Crucell	Director, Quality Control
Crucell	VP Process Development
Cytheris SA	Director of Process Development
Cytheris SA	Director Development of Chemical and Bio-Chemical
Cancer Research UK	Head of Biotherapeutics Development Unit
CHR Hansen	Director Supply Chain
CHR Hansen	General Manger

COMPANY	TITLE
CHR Hansen	Senior Director Bio Process
Chugai Pharmaceuticals	Associate Director Manufacturing Science and Technologies
Chugai Pharmaceuticals	Associate Director Process Development
Coretherapix	Head of Cell & Gene Technology
Dimension Therapeutics	Head of Development
Eli Lilly	Director Quality & Compliance
Eli Lilly	Manager, Upstream Technology
Elan	Senior Director Technology & Operation
EMEA	Director Quality Assessment
FDA	Director
EMD Serono	Downstream Manager
Genentech	VP, Operational Excellence
Genzyme	Director, Cell & Gene Therapy
Glaxo Smith Kline	Head of Downstream Processing, Biopharm Process Research
Glaxo Smith Kline	Head of Gene Therapy
Glaxo Smith Kline	Director, Operational Excellence
Glaxo Smith Kline	Director Quality Technologies & QbD Implementation
Hospira	Director Global Biologics
Institute of Operational Excellence	Founder
Jansen BV	Section Leader, Upstream Process Development,
Jansen BV	Snr Tech Director
Jansen BV	Senior Manager Purification
Lek Pharmaceuticals	Head of Innovation DSP Development
Lek Pharmaceuticals	Upstream Manufacturing Manager
Lonza	Associate Director, Process Transfer and Development
Lonza	Head of PCP, Exclusive Synthesis
Macrogenics	Quality Director
FDA	Associate Director
FDA	Senior Director Technical Operations
Medimmune	Assoc. Director for Manufacturing Science and Technology
Medimmune	Director Operational Excellence
Medimmune	Director, Supply Chain
Merck	Senior Manager, Expression & Purification.
Merck	Director Cultivation Stem Cell Manufacturing
Merck	Senior Manager, Protein Expression & Purification.
Merck	Director Cultivation Biopharmaceutical Manufacturing
UniQure	VP Regulatory Compliance

COMPANY	TITLE
Mylan	Vice-President and Head of Global Biologics Research & Development
Merck Serano	Bioprocess & Innovation Manager
Merck Serano	Director of Technical Development Biosimilars
Merck Serano	Principle Scientist Upstream Fermentation
Miltenyi Biotec GmbH	VP Supply Chain
Miltenyi Biotec GmbH	Project Manager R & D Bioprocess Sciences
Miltenyi Biotec GmbH	Head of R&D Recombinant Proteins
NovoNordisk	Director Raw Materials
NovoNordisk	Director, Process Development
Octapharma	Head of Upstream Processing Unit
Novartis	Lab Head, Novartis Vaccines and Diagnostics
Novartis	Director Bioprocess Development
Novartis	Principle Scientist Purification
Novartis	Director Supply Chain
Pfizer	Site Cell Culture Lead
Pfizer	Site Purification Lead
Pfizer	Director Quality Assurance
Pfizer	Biological CoE Director
Pfizer	Site OE Lead, Pfizer Global Manufacturing
Pfizer	Senior Director of Cell Line Development
Regeneron	Senior Director, Process Development
Regeneron	Director, Process Development
Resentia	Senior VP Process Development & Manufacturing
Roche	Operations Director
Roche	Purification Manager
Roche	Head of Cell Culture
Sandoz	Head of DSP Development Cell Culture
Sanofi	VP Process Development
Sanofi Pasteur	VP Global Manufacturing Technology
Sisene	Manager Purification
Shire	Associate Director, Cell Culture Development
SOBI	Senior Scientist Downstream Processing
Statens Serum Institut A/S	Director, Downstream Processing
Takada	Director, Manufacturing Science & Technology
Takada	Head of BioProcess
Theravectys	CSO
UniQure	VP Regulatory Compliance
UCB	Director, Process Development

## REGISTER

**Book Online:** [www.cgt-development.com/delegate-package.html](http://www.cgt-development.com/delegate-package.html)

**Tel** : +44 (0) 203 699 8500

**Email** : [delegates@wwresearch.net](mailto:delegates@wwresearch.net)

**Mail** : Weiser West Research, 25 Cabot Square, London E14 4QZ.

## SPECIAL DISCOUNTS

- **15% discount – 2 delegates**
- **20% discount – 3 delegates**
- **25% discount – 4 or more delegates**

Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

## VENUE

**The Marriot Waterfront, Boston, USA**

**to CGT-development Innovation Summit Delegates:  
Up to 40% off room rates!**

For enquires feel free to contact us:  
+44 (0) 203 699 8500

## DELEGATE PACKAGE SUMMARY

- Access To Over 60 Presentations
  - Scheduled Master-Class & Workshops
  - One Delegate Pass
  - Networking Meetings
  - Gala Dinner
  - Full Hospitality For Both Days.
- Delegate Fee: £1650**

**cgt-development**  
**GLOBAL INNOVATION CONGRESS 2025**

Weiser West Research produces and manages leading global summits Exclusively for the Pharmaceutical and Life Science industry.

We aim in help pioneering leaders boost success and growth by providing the perfect modern era networking platform that is highly informative and delivers a dynamic cohesive environment to benchmark, learn, engage, procure and interact at the very highest level.

[www.wwresearch.net](http://www.wwresearch.net)

**Rene Labatut**  
Vice President  
Biologics Technology  
Innovation Strategy

**sanofi**

“  
Great Content.  
First Class  
Networking  
and Service  
”